Efavirenz Completed Phase 1 Trials for Human Immunodeficiency Virus (HIV)

IndicationsStatusPurposePhase
CompletedNot Available1
clinicaltrials.gov IdentifierTitleDrugs
NCT01268839A Phase I, Open-label Trial to Explore the Pharmacokinetics, Safety and Tolerability of TMC278 (Rilpivirine) 25 mg Once Daily Following a 2-week Period Receiving Efavirenz, in Healthy Male and Female Volunteers